title: Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors.forename: M
authors.initials: M
authors.lastname: Othus
authors.affiliation: Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors.forename: S
authors.initials: S
authors.lastname: Mukherjee
authors.affiliation: Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Sekeres
authors.affiliation: Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA.
authors.forename: J
authors.initials: J
authors.lastname: Godwin
authors.affiliation: Seattle Genetics, Seattle, WA, USA.
authors.forename: S
authors.initials: S
authors.lastname: Petersdorf
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors.forename: F R
authors.initials: FR
authors.lastname: Appelbaum
authors.affiliation: Division of Hematology & Oncology, University of Alabama, Birmingham, AL, USA.
authors.forename: H
authors.initials: H
authors.lastname: Erba
authors.affiliation: Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
authors.forename: E
authors.initials: E
authors.lastname: Estey
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017410:Practice Guidelines as Topic
chemical_list: D003561:Cytarabine; D015255:Idarubicin; D003630:Daunorubicin